Download this slideset from a live symposium at AACR 2023 to review expert perspectives on structural features and current clinical data with TROP2-targeted antibody-drug conjugates, with a focus on use of these agents in breast and lung cancers.
Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts
Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute of Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer The University of Texas MD Anderson Cancer Center Houston, Texas
Paolo Tarantino, MD
Advanced Research Fellow Harvard Medical School Department of Breast Oncology Dana-Farber Cancer Institute Boston, Massachusetts
Provided by Clinical Care Options, LLC
Supported by educational grants: AstraZeneca and Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc.
Select date of attendance
Welcome to the CCO site
Thank you for your interest in CCO content. As a guest, please complete the following information. This data helps ensure our continued delivery of impactful medical education.
You will be sent to the previous page if you close this window.